STOCK TITAN

Roivant Sciences Ltd. - ROIV STOCK NEWS

Welcome to our dedicated page for Roivant Sciences Ltd. news (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences Ltd. stock.

Roivant Sciences Ltd. (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to revolutionize healthcare by accelerating the development and commercialization of crucial medicines. With a mission to bring innovative treatments to market swiftly, Roivant builds nimble subsidiaries known as 'Vants' to optimize efficiency in pharma R&D and commercialization.

Roivant’s diversified pipeline includes VTAMA®, a novel topical approved for psoriasis and in development for atopic dermatitis, along with other promising drug candidates such as batoclimab, IMVT-1402, and brepocitinib. These candidates are being developed for various autoimmune and inflammatory conditions, including non-infectious uveitis, dermatomyositis, and other IgG-mediated autoimmune indications.

The company’s strategy involves forming strategic partnerships with leading academic institutions and biopharmaceutical companies to enhance its therapeutic portfolio. Notably, collaborations with Takeda, Priovant, and Immunovant have bolstered its drug development capabilities.

Recent advancements include significant progress in clinical trials, such as positive Phase 2 results for brepocitinib in non-infectious uveitis and the successful launch of VTAMA for psoriasis. Additionally, Roivant's acquisition of Telavant and robust financial performance underscore its growth trajectory and commitment to addressing unmet medical needs.

Roivant’s innovative approach also extends to incubating discovery-stage companies and health technology startups, ensuring a continuous pipeline of next-generation therapies. The company’s forward-thinking model focuses on areas with high societal medical needs, aiming to deliver impactful solutions to patients globally.

For more detailed and up-to-date information on Roivant Sciences Ltd., visit their official website.

Rhea-AI Summary

Roivant (Nasdaq: ROIV) reported its Q4 and FY2024 results, highlighting strong performance in clinical trials and significant debt reductions.

Key points include:

  • Brepocitinib showed the best treatment failure rates in non-infectious uveitis (NIU), supporting a pivotal program initiation in H2 2024.
  • VTAMA net product revenue reached $75.1M, with over 385,000 prescriptions since launch.
  • Roivant renegotiated Dermavant’s debt, reducing potential cash payments by over $300M, with $225M savings expected over the next three fiscal years.
  • The company has $6.6B in cash, supporting a runway into profitability.
  • A $1.5B share repurchase program was approved, reducing outstanding shares by 9%.
  • Net loss for Q4 was $108M, while annual R&D expenses decreased by $23.5M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
-
Rhea-AI Summary

Roivant (Nasdaq: ROIV) announced a live conference call and webcast scheduled for 8:00 a.m. ET on May 30, 2024, to discuss its fourth-quarter and fiscal year results ending March 31, 2024. The company will also provide a business update during this session. Investors can register online for the conference call. The presentation will be available under the 'Events & Presentations' section of Roivant’s website, where the archived webcast will also be accessible post-call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences earnings
-
Rhea-AI Summary
Roivant and Kinevant Sciences have completed enrollment in the RESOLVE-Lung Phase 2 study evaluating namilumab for chronic pulmonary sarcoidosis. Namilumab inhibits GM-CSF to target the underlying cause of the disease. The topline results are expected by the end of 2024. Sarcoidosis affects millions globally, and this study aims to provide a new treatment option for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
Rhea-AI Summary
Roivant (ROIV) announces a $1.5 billion share repurchase program and positive Phase 2 study results for brepocitinib in non-infectious uveitis (NIU). The repurchase includes buying back Sumitomo Pharma's stake, reducing shares outstanding by 9%. NEPTUNE study shows promising efficacy data, with Treatment Failure rates of 29% for 45 mg and 44% for 15 mg. Brepocitinib demonstrates potential as a multi-blockbuster franchise in specialty autoimmunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
buyback
-
Rhea-AI Summary
Roivant (ROIV) reports strong financial results for Q3 2023, completes $7.1B sale of Telavant to Roche, and achieves positive clinical trial results for Batoclimab and VTAMA products. The company maintains a healthy cash position of $6.7B, supporting future growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
-
Rhea-AI Summary
Roivant (ROIV) will host a live conference call and webcast to report its financial results for the third quarter ended December 31, 2023, and provide a business update on February 13, 2024. The conference call details can be accessed on the Roivant website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences earnings
Rhea-AI Summary
Immunovant, Inc. (Nasdaq: IMVT) announced promising results from the initial cohort of patients in a 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease. The trial demonstrated a meaningful response rate of over 50%, with potential best-in class IgG reduction of up to 87% after 12 weeks of treatment. The primary and secondary outcome measurements of the trial are being measured at weeks 12 and 24, showing a dose response on efficacy between different regimens of batoclimab. The treatment was generally well-tolerated with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
-
Rhea-AI Summary
Roivant (Nasdaq: ROIV) completes the acquisition of Telavant by Roche (SIX: RO, ROG; OTCQX: RHHBY) for $7.1 billion, with an upfront payment and a near-term milestone payment. Telavant holds rights to RVT-3101, a therapy for inflammatory bowel disease in the US and Japan. Roivant previously owned 75% of Telavant's shares. Roche aims to continue RVT-3101's development across multiple indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
-
Rhea-AI Summary
Immunovant, Inc. (IMVT) announced initial data from the 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402, showing that four subcutaneously administered doses of 600 mg produced a mean IgG reduction similar to high dose batoclimab, with minimal changes in albumin and LDL-C, confirming the potential of IMVT-1402 as a best-in-class FcRn inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
Rhea-AI Summary
Roivant (ROIV) and Priovant announce that the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 (SRI-4) at Week 52. However, Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) due to the drug’s favorable safety and tolerability profile, six other positive phase 2 studies, and active arm performance in this study. Priovant also expects to announce topline results from the Phase 2 POC study of brepocitinib in non-infectious uveitis (NIU) in the first quarter of calendar year 2024 and topline results from the Phase 3 trial in dermatomyositis (DM) in calendar year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags

FAQ

What is Roivant Sciences Ltd. known for?

Roivant Sciences Ltd. is known for its innovative approach to rapidly developing and commercializing new medicines, primarily through its nimble subsidiaries called 'Vants'.

What are the key products in Roivant's pipeline?

Key products include VTAMA® for psoriasis, batoclimab and IMVT-1402 for autoimmune conditions, and brepocitinib for dermatomyositis and non-infectious uveitis.

What is the goal of Roivant’s business model?

The goal of Roivant’s business model is to accelerate the development and commercialization of important medicines, ensuring they rapidly reach patients with serious diseases.

Who are some of Roivant’s strategic partners?

Roivant has partnered with leading academic institutions and biopharmaceutical companies, including Takeda, Priovant, and Immunovant.

What recent achievements has Roivant made?

Recent achievements include positive Phase 2 trial results for brepocitinib in non-infectious uveitis and the commercial launch of VTAMA for psoriasis.

How does Roivant's 'Vant' model work?

Roivant’s 'Vant' model involves creating nimble, entrepreneurial biotech companies that specialize in developing and commercializing specific medicines and technologies efficiently.

What is VTAMA® used for?

VTAMA® is a novel topical treatment approved for psoriasis and is also being developed for atopic dermatitis.

How does Roivant contribute to innovation in drug development?

Roivant accelerates innovation by reducing the time and cost of drug development, leveraging technology, and forming strategic collaborations to drive efficiency in R&D.

Why is Roivant’s approach significant?

Roivant’s approach is significant because it addresses areas with high unmet medical needs, ensuring that vital medications reach patients faster and more cost-effectively.

Where can I find more information about Roivant?

More information about Roivant Sciences Ltd. can be found on their official website at www.roivant.com.

Roivant Sciences Ltd.

Nasdaq:ROIV

ROIV Rankings

ROIV Stock Data

8.38B
738.72M
22.49%
72.68%
5.42%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
HAMILTON HM11